Reportlinker.com announces that a new market research report is available in its catalogue:
Stem Cells - The Hype and the Hope 2010-2025
http://www.reportlinker.com/p0210913/Stem-Cells---The-Hype-and-the-Hope-2010-2025.html
Report Details
- what commercial prospects for those technologies in medicine?
In 2010, the stem cells market stands on the brink of technological and commercial breakthroughs, our new study explains. For the first time, pharmaceutical companies are beginning to invest significantly in the drive to create new treatments based on embryonic and adult stem cells. As this research gathers pace, with clinical trials commencing, the potential of stem cells in medicine may relatively soon be fulfilled. Results in animals indicate that stem cells may provide treatment options for a range of disorders and restorative applications including multiple sclerosis, diabetes, Parkinson's disease, Alzheimer's disease, spinal cord injury, blindness, immune system disorders and cardiovascular disease.
Stem Cells - The Hype and the Hope 2010-2025 provides an analytical overview of this burgeoning sector, with technologies and commercial potential discussed and forecasted. The sector will gather momentum as stem cell therapies start to emerge from the R&D pipeline from this decade onwards. In this report we assess the disease areas in which stem cell therapies are most likely to emerge, with overviews of the commercial and academic research being carried out in subsectors of healthcare. We analyse the short-, medium- and long-term prospects for stem cell breakthroughs in disease areas, providing the information that you require.
Our new report also provides a review of leading companies that currently seek to harness stem cell technologies. The research areas of each company are profiled, with discussion of the approaches being used. Some organisations are developing scalable therapies with allogeneic stem cells, while others investigate personalised treatments using autologous stem cells. Other organisations pursue research in the embryonic stem cells field, which has opened up in the US, with fewer obstacles and greater funding opportunities available since 2009. Some companies already generate revenues from stem cells by carving out market niches in stem cell supply, such as stem cells for drug development and toxicity assays, or services such as stem cell banking in umbilical cord blood. We analyse the main divisions of the market, providing revenue forecasts for 2010 to 2025.
Comprehensive analysis of the global stem cells market
Stem Cells - The Hype and the Hope 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are comprehensive tables and figures, as well as four interviews with experts. The result is a detailed market- and industry-centred study, with analyses and informed opinion to benefit your work.
Why you should buy Stem Cells - The Hype and the Hope 2010-2025
This report gives you the following benefits in particular:
• You will receive a comprehensive analysis of the prospects for stem cells from 2010 to 2025, including predicted revenues, growth rates and other data for the overall market and its main divisions
• You will find out where the market is heading - technologically and commercially - from the present onwards, both for the global market and for leading national markets
• You will discover prospects for leading companies and therapy areas, with predictions of where main breakthroughs are likely to come from 2010 to 2025
• You will identify significant R&D developments as well as up-and-coming technologies and products